Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging agent could sharpen cancer detection

NCT ID NCT04499365

Recruiting now Diagnosis Sponsor: First Affiliated Hospital of Fujian Medical University Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial evaluates a radioactive tracer called 68Ga-DOTA/NOTA-FAPI-04, given as a single injection before a PET/CT scan, to see if it can better identify primary tumors and metastases in people with various cancers. Researchers will measure how strongly the tracer accumulates in suspicious lesions using a standard value called SUV. The study includes 500 adults with suspected, newly diagnosed, or previously treated malignant tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive tracer called 68Ga-DOTA/NOTA-FAPI-04, injected once before a PET/CT scan
What this could lead to
If successful, this imaging method could improve the detection of cancer spread, helping doctors plan more accurate treatments.
What could go wrong
This is an early-phase study, so the tracer may not prove more effective than existing scans. Results are based on imaging measures, not patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTASIS POSITRON EMISSION TOMOGRAPHY TUMOR

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, 350005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.